CRMD logo

CRMD
CorMedix Inc

22,842
Mkt Cap
$843.04M
Volume
1.81M
52W High
$17.43
52W Low
$5.60
PE Ratio
14.41
CRMD Fundamentals
Price
$11.01
Prev Close
$10.78
Open
$10.59
50D MA
$11.63
Beta
1.08
Avg. Volume
2.41M
EPS (Annual)
-$0.3046
P/B
3.64
Rev/Employee
$668,802.61
Loading...
Loading...
News
all
press releases
IOVA Soars 28% on Narrower-Than-Expected Loss in Q3, Revenues Up Y/Y
Iovance's shares jump 28% as the biotech narrows its quarterly loss and lifts gross margins amid strong Amtagvi sales and cost cuts.
Zacks·19h ago
News Placeholder
More News
News Placeholder
Allogene Posts Narrower-Than-Expected Loss in Q3, Nil Sales
ALLO's Q3 loss narrows to 19 cents per share, beating estimates, as R&D and G&A costs decline despite no product sales.
Zacks·21h ago
News Placeholder
Revolution Medicines Posts Wider-Than-Expected Loss in Q3, Sales Nil
RVMD posts a wider Q3 loss as rising R&D and administrative costs weigh, while its RAS(ON) pipeline advances toward key 2026 data.
Zacks·2d ago
News Placeholder
JAZZ Beats on Q3 Earnings & Sales, Narrows '25 Sales View
Jazz Pharmaceuticals posts strong Q3 results with higher EPS and sales, aided by a tax benefit and robust neuroscience growth.
Zacks·2d ago
News Placeholder
Viatris Tops Q3 Earnings & Revenue Estimates, Ups '25 Guidance
Viatris tops Q3 earnings and revenue estimates, lifts 2025 outlook, and expands its Japan presence with Aculys Pharma deal.
Zacks·2d ago
News Placeholder
Perrigo Q3 Earnings Beat, Sales Miss, Stock Falls on '25 View Cut
PRGO beats Q3 earnings estimates but misses on sales. It also trims the 2025 outlook and launches a strategic review of its infant formula unit.
Zacks·3d ago
News Placeholder
Amicus' Q3 Earnings Beat, Higher Product Sales Drive Y/Y Revenues
FOLD's third-quarter earnings top estimates as rising Galafold and Pombiliti + Opfolda sales lift revenues by 19% year over year.
Zacks·3d ago
News Placeholder
Bet on 5 Top-Ranked Stocks With Rising P/E
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include The Chef's Warehouse, Life Time Group Holdings, The Honest Company, CorMedix and Boston Scientific.
Zacks·3d ago
News Placeholder
All You Need to Know About CorMedix (CRMD) Rating Upgrade to Strong Buy
CorMedix (CRMD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·4d ago
News Placeholder
New Strong Buy Stocks for November 4th
CRMD, GWRE, TNET, UHS and ISBA have been added to the Zacks Rank #1 (Strong Buy) List on Nov. 4, 2025.
Zacks·4d ago

Latest CRMD News

View

Advertisement|Remove ads.

Advertisement|Remove ads.